• *
  Adult patients with insufficiently controlled type 2 diabetes and CAD, PAD, or a history of MI or stroke.
• ¤
  Incident or worsening nephropathy is defined as progression to macroalbuminuria, doubling of serum creatinine, eGFR of ≤45 mL/min/1.73 m²; initiation of renal replacement therapy; death from renal disease. 
  Incident or worsening nephropathy was a prespecified component of the secondary microvascular outcome in the EMPA-REG OUTCOME® trial.
• ‡
  Pooled data from 10 mg and 25 mg doses of Empagliflozin; both doses showed a comparable reduction in the risk of incident or worsening nephropathy.

References:

• 1.
  Local SMPC Empagliflozin (Summary of Product Characteristics). May 2022
• 2.
  Wanner C, Inzucchi S, Lachin J, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375(4):323-334.